Key Takeaways:
Investors who bought Insulet securities between Feb. 21, 2025 and May 26, 2026 have until Aug. 31 to seek lead plaintiff status.
"Insulet investors who suffered losses should contact the firm directly to discuss their options," James (Josh) Wilson, securities litigation partner at Faruqi & Faruqi, said.
The lawsuit, Hu v. Insulet Corporation, No. 26-cv-013062 (D. Mass.), charges Insulet and certain current and former executives with violating the Securities Exchange Act of 1934. The complaint alleges Insulet's manufacturing controls and procedures were defective, creating a foreseeable risk that products would violate safety regulations or pose injury risk, and that the manufacturing issue behind its March 2026 Medical Device Correction affected more Omnipod products than the company claimed.
On March 12, 2026, Insulet disclosed a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through product monitoring. The stock fell nearly 7 percent. On May 26, 2026, Insulet disclosed another correction covering Omnipod 5, Omnipod Dash and Omnipod Eros Pods over a manufacturing issue that could result in insulin under-delivery. Shares fell more than 5 percent. The two corrections came within roughly two months, compounding investor losses as shares slid from earlier 2026 levels.
The Private Securities Litigation Reform Act of 1995 lets any investor who bought Insulet securities during the class period seek appointment as lead plaintiff, typically the movant with the greatest financial interest who is also typical and adequate of the class. The lead plaintiff directs the litigation and can select counsel. An investor's ability to share in any potential recovery does not depend on serving as lead plaintiff. Rosen Law Firm and Robbins Geller Rudman & Dowd have also publicized related claims.
Insulet, a maker of insulin delivery systems including the Omnipod line founded in 2000 and based in Acton, Massachusetts, has a market capitalization of about $9.95 billion; shares last closed at $143.41. The company reported $2.71 billion in trailing revenue and net income of $247.1 million, with earnings per share of $3.48.
The Aug. 31 deadline tests whether investors consolidate the case under a lead plaintiff before the court. Insulet's next catalyst is the lead plaintiff ruling and any subsequent settlement or trial proceedings.
This article is for informational purposes only and does not constitute investment advice.
